Role of prostaglandins in angiotensin-induced steroidogenesis

Absence of an effect by prostaglandin E2

W. B. Campbell, C. E. Gomez-Sanchez, B. V. Adams

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Recently, we have found that the prostaglandin synthesis inhibitor, indomethacin, reduced basal and angiotensin stimulated aldosterone release. To further test the possibility that prostaglandins (PGs) function as mediators of adrenal steroidogenesis, we examined the release of aldosterone, PGE2, and PGF2(α) under basal and stimulated conditions in isolated adrenal capsular cells in vitro. Angiotensin II and III caused a dose-related increase in aldosterone release without significantly altering the release of PGE2 or PGF2(α). Indomethacin inhibited basal, angiotensin II, and angiotensin III-induced steroidogenesis by 40%, 15% and 52% respectively. Additionally, it inhibited the release of PGE2 by 60% in the control and angiotensin-treated cells. In indomethacin-treated cells, PGE2 stimulated aldosterone release in supraphysiologic doses; however, its steroidogenic effect was not additive with angiotensin II. The prostaglandin precursor, arachidonic acid, increased the adrenal synthesis of PGE2 and PGF2(α) in a dose-related manner without altering the synthesis of aldosterone. Similarly, the prostaglandin endoperoxide PGH2 increased the synthesis of PGE2 by 250-fold, yet failed to alter aldosterone synthesis. These findings indicate that PGE2 does not mediate or modulate basal or angiotensin-stimulated steroidogenesis. Furthermore, it would appear that indomethacin may inhibit adrenal steroidogenesis via a mechanism other than inhibition of prostaglandin synthesis.

Original languageEnglish (US)
Pages (from-to)471-476
Number of pages6
JournalHypertension
Volume2
Issue number4
StatePublished - 1980

Fingerprint

Angiotensins
Dinoprostone
Prostaglandins
Aldosterone
Indomethacin
Dinoprost
Angiotensin III
Angiotensin II
Prostaglandin Endoperoxides
Prostaglandin H2
Prostaglandin Antagonists
Arachidonic Acid

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Role of prostaglandins in angiotensin-induced steroidogenesis : Absence of an effect by prostaglandin E2. / Campbell, W. B.; Gomez-Sanchez, C. E.; Adams, B. V.

In: Hypertension, Vol. 2, No. 4, 1980, p. 471-476.

Research output: Contribution to journalArticle

@article{88f9fc959a9f481fbd779be93bed8a7d,
title = "Role of prostaglandins in angiotensin-induced steroidogenesis: Absence of an effect by prostaglandin E2",
abstract = "Recently, we have found that the prostaglandin synthesis inhibitor, indomethacin, reduced basal and angiotensin stimulated aldosterone release. To further test the possibility that prostaglandins (PGs) function as mediators of adrenal steroidogenesis, we examined the release of aldosterone, PGE2, and PGF2(α) under basal and stimulated conditions in isolated adrenal capsular cells in vitro. Angiotensin II and III caused a dose-related increase in aldosterone release without significantly altering the release of PGE2 or PGF2(α). Indomethacin inhibited basal, angiotensin II, and angiotensin III-induced steroidogenesis by 40{\%}, 15{\%} and 52{\%} respectively. Additionally, it inhibited the release of PGE2 by 60{\%} in the control and angiotensin-treated cells. In indomethacin-treated cells, PGE2 stimulated aldosterone release in supraphysiologic doses; however, its steroidogenic effect was not additive with angiotensin II. The prostaglandin precursor, arachidonic acid, increased the adrenal synthesis of PGE2 and PGF2(α) in a dose-related manner without altering the synthesis of aldosterone. Similarly, the prostaglandin endoperoxide PGH2 increased the synthesis of PGE2 by 250-fold, yet failed to alter aldosterone synthesis. These findings indicate that PGE2 does not mediate or modulate basal or angiotensin-stimulated steroidogenesis. Furthermore, it would appear that indomethacin may inhibit adrenal steroidogenesis via a mechanism other than inhibition of prostaglandin synthesis.",
author = "Campbell, {W. B.} and Gomez-Sanchez, {C. E.} and Adams, {B. V.}",
year = "1980",
language = "English (US)",
volume = "2",
pages = "471--476",
journal = "Hypertension",
issn = "0194-911X",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Role of prostaglandins in angiotensin-induced steroidogenesis

T2 - Absence of an effect by prostaglandin E2

AU - Campbell, W. B.

AU - Gomez-Sanchez, C. E.

AU - Adams, B. V.

PY - 1980

Y1 - 1980

N2 - Recently, we have found that the prostaglandin synthesis inhibitor, indomethacin, reduced basal and angiotensin stimulated aldosterone release. To further test the possibility that prostaglandins (PGs) function as mediators of adrenal steroidogenesis, we examined the release of aldosterone, PGE2, and PGF2(α) under basal and stimulated conditions in isolated adrenal capsular cells in vitro. Angiotensin II and III caused a dose-related increase in aldosterone release without significantly altering the release of PGE2 or PGF2(α). Indomethacin inhibited basal, angiotensin II, and angiotensin III-induced steroidogenesis by 40%, 15% and 52% respectively. Additionally, it inhibited the release of PGE2 by 60% in the control and angiotensin-treated cells. In indomethacin-treated cells, PGE2 stimulated aldosterone release in supraphysiologic doses; however, its steroidogenic effect was not additive with angiotensin II. The prostaglandin precursor, arachidonic acid, increased the adrenal synthesis of PGE2 and PGF2(α) in a dose-related manner without altering the synthesis of aldosterone. Similarly, the prostaglandin endoperoxide PGH2 increased the synthesis of PGE2 by 250-fold, yet failed to alter aldosterone synthesis. These findings indicate that PGE2 does not mediate or modulate basal or angiotensin-stimulated steroidogenesis. Furthermore, it would appear that indomethacin may inhibit adrenal steroidogenesis via a mechanism other than inhibition of prostaglandin synthesis.

AB - Recently, we have found that the prostaglandin synthesis inhibitor, indomethacin, reduced basal and angiotensin stimulated aldosterone release. To further test the possibility that prostaglandins (PGs) function as mediators of adrenal steroidogenesis, we examined the release of aldosterone, PGE2, and PGF2(α) under basal and stimulated conditions in isolated adrenal capsular cells in vitro. Angiotensin II and III caused a dose-related increase in aldosterone release without significantly altering the release of PGE2 or PGF2(α). Indomethacin inhibited basal, angiotensin II, and angiotensin III-induced steroidogenesis by 40%, 15% and 52% respectively. Additionally, it inhibited the release of PGE2 by 60% in the control and angiotensin-treated cells. In indomethacin-treated cells, PGE2 stimulated aldosterone release in supraphysiologic doses; however, its steroidogenic effect was not additive with angiotensin II. The prostaglandin precursor, arachidonic acid, increased the adrenal synthesis of PGE2 and PGF2(α) in a dose-related manner without altering the synthesis of aldosterone. Similarly, the prostaglandin endoperoxide PGH2 increased the synthesis of PGE2 by 250-fold, yet failed to alter aldosterone synthesis. These findings indicate that PGE2 does not mediate or modulate basal or angiotensin-stimulated steroidogenesis. Furthermore, it would appear that indomethacin may inhibit adrenal steroidogenesis via a mechanism other than inhibition of prostaglandin synthesis.

UR - http://www.scopus.com/inward/record.url?scp=0019141078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019141078&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 471

EP - 476

JO - Hypertension

JF - Hypertension

SN - 0194-911X

IS - 4

ER -